Vivos RDGL

Vivos Inc is a radiation oncology medical device company engaged in the development of its yttrium 90 based precision radionuclide therapy devices. The company creates RadioGel for human therapy and IsoPet for veterinary use. It also produces PLGA g PEG polymers and PrecisionGel a hydrogel platform for delivering active pharmaceutical ingredients. Vivos works with scientists engineers and strategic partners including national laboratories universities and private corporations to advance its technology. Its vision is to empower physicians researchers veterinarians and patients with new isotope technologies and polymer solutions for safe effective cancer treatment in humans and animals.

Vivos generates revenue primarily from the sale of its RadioGel and IsoPet devices for human and veterinary oncology. Additional income comes from the sale of PLGA g PEG polymers and PrecisionGel hydrogel products. The company also charges fees for certifying veterinary clinics to administer IsoPet therapy and may earn revenue from future licensing or partnership agreements.

Vivos operates through two main segments the Human Therapy Division and the Animal Therapy Division.

• Human Therapy Division focuses on the RadioGel device an injectable particle gel that incorporates yttrium 90 phosphate particles within a thermosensitive hydrogel to deliver localized beta radiation to solid tumors while sparing surrounding healthy tissue. The division is working toward obtaining FDA clearance for RadioGel as a Class II medical device and is pursuing clinical trials in India and the United States to support regulatory approval.
• Animal Therapy Division markets IsoPet the veterinary version of the yttrium 90 based gel for treating solid tumors in dogs cats horses and other animals. Because veterinary medical devices do not require premarket approval in the United States IsoPet is cleared for commercial distribution provided it is safe effective and properly labeled. The division also runs a certification program for veterinary clinics and has expanded its network of certified treatment centers across the country.

Vivos occupies a niche in the radiation oncology market where its yttrium 90 based brachytherapy approach competes with traditional seed based therapies such as iodine 125 palladium 103 and cesium 131 implants. The company differentiates itself through the short range of beta emissions which allows high dose delivery to the tumor with minimal exposure to healthy tissue and through the biocompatible hydrogel that resorbs after treatment leaving only microscopic phosphate particles. Competitors include established firms like C R Bard Eckert Ziegler and GT MedTech as well as newer entrants developing alternative radionuclide therapies.

Vivos serves veterinary clinics universities and private practices that have been certified to use IsoPet for treating canine feline equine and exotic animal tumors. Specific customers include Vista Veterinary Hospital in Kennewick Washington University of Missouri in Columbia Johns Hopkins University in Baltimore Indian Creek Veterinary Hospital in Fort Wayne Hopkinton Animal Hospital in Weare NorthStar VETS in Robbinsville Animal Emergency and Specialty Center of Knoxville Sumner Veterinary Hospital in Sumner Washington New England Equine Practice in Patterson New York Myhre Equine Clinic in Rochester New Hampshire University of Wisconsin School of Veterinary Medicine University of Illinois College of Veterinary Medicine Brazos Equine Hospital in Navasota Texas University of Florida Large Animal Hospital Capital Veterinary Specialists University of Florida Small Animal Hospital and Sun City Veterinary Surgical Center in El Paso Texas. For human applications the company targets hospitals oncology centers and interventional radiologists that treat non resectable solid tumors.